Table 5 Dose-independent Potentially Inappropriate Medications (PIMs) by age and gender [n (%)]
|  | total N = 2069 | 70–79 N = 1186 | ≥80 N = 883 | p-value |
|---|---|---|---|---|
PIMs total | 311 (15) | 173 (15) | 139 (16) | 0.47 |
PIM: ATC subgroup (n = 311) | ||||
 psychoanaleptics (N06) | 63 (20) | 37 (22) | 26 (19) | 0.54 |
 psycholeptics (N05) | 59 (19) | 30 (17) | 30 (21) | 0.35 |
 antihypertensives (C02) | 44 (14) | 22 (13) | 22 (16) | 0.42 |
 calcium channel blockers (C08) | 34 (11) | 16 (9) | 18 (13) | 0.30 |
 drugs for obstructive airway diseases (R03) | 33 (10) | 23 (13) | 9 (7) | 0.049 |
 urologicals (G04) | 30 (10) | 16 (9) | 14 (10) | 0.81 |
 antiinflammatory and antirheumatic products (M01) | 24 (8) | 14 (8) | 10 (7) | 0.77 |
 cardiac therapy (C01) | 20 (7) | 11 (6) | 9 (7) | 0.95 |
|  | total N = 2069 | male N = 762 | female N = 1307 | p-value |
PIMs total | 311 (15) | 104 (14) | 208 (16) | 0.17 |
PIM: ATC subgroup (n = 311) | ||||
 psychoanaleptics (N06) | 63 (20) | 19 (18) | 44 (21) | 0.55 |
 psycholeptics (N05) | 59 (19) | 13 (12) | 46 (22) | 0.039 |
 antihypertensives (C02) | 44 (14) | 20 (20) | 24 (11) | 0.061 |
 calcium channel blockers (C08) | 34 (11) | 12 (12) | 21 (10) | 0.69 |
 drugs for obstructive airway diseases (R03) | 33 (10) | 11 (10) | 22 (11) | 1.0 |
 urologicals (G04) | 30 (10) | 9 (9) | 20 (10) | 0.79 |
 antiinflammatory and antirheumatic products (M01) | 24 (8) | 9 (9) | 15 (7) | 0.65 |
 cardiac therapy (C01) | 20 (7) | 7 (7) | 13 (6) | 0.85 |